误诊为血管免疫母T细胞淋巴瘤的Castleman病1例

元博琳; 孙彩凤; 王椋; 刘国强

doi:10.16766/j.cnki.issn.1674-4152.004558

误诊为血管免疫母T细胞淋巴瘤的Castleman病1例

doi: 10.16766/j.cnki.issn.1674-4152.004558

1.
山东第二医科大学临床医学院，山东潍坊 261000
2.
胜利油田中心医院血液内科，山东东营 257034

详细信息

通讯作者:
王椋，E-mail: 18654620224@163.com

中图分类号: R551.2 R733.4
计量
- 文章访问数: 6
- HTML全文浏览量: 4
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2025-06-28
- 网络出版日期: 2026-11-10

A case of castleman disease misdiagnosed as angioimmunoblastic T-cell lymphoma

1.
School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong 261000, China

摘要

摘要: Castleman病和血管免疫母细胞性T细胞淋巴瘤两种疾病在组织学上存在一些相似性，如淋巴结内的细胞排列、细胞形态等。这种相似性可能导致在临床和病理诊断中出现误诊的情况；两者在临床表现结果上也可能有一些重叠，增加了鉴别诊断的难度。本文报道1例Castleman病误诊为血管免疫母细胞性T细胞淋巴瘤的患者的诊疗经过，旨在降低误诊率，提高临床上对该类疾病的判断能力。
- Castleman病 /
- 血管免疫母T细胞淋巴瘤 /
- 误诊 /
- 淋巴结活检
Abstract: Castleman disease and angioimmunoblastic T-cell lymphoma share certain histological similarities, such as cellular arrangement and cell morphology within the lymph nodes. These similarities may lead to misdiagnosis in clinical and pathological practice. Additionally, there may be some overlap in their clinical manifestations, further increasing the difficulty of differential diagnosis. This article reports the diagnosis and treatment process of a patient initially diagnosed with angioimmunoblastic T-cell lymphoma but later confirmed as Castleman disease, aiming to reduce the misdiagnosis rate and improve clinical decision-making regarding such diseases.
- Castleman disease /
- Angioimmunoblastic T cell lymphoma /
- Misdiagnosis /
- Lymph node biopsy

HTML全文

图 1 Castleman病患者右侧腋窝淋巴结活检病理

Figure 1. Biopsy of right axillary lymph node in Castleman's disease

下载: 全尺寸图片幻灯片

参考文献(17)

[1]	陈冬, 裴仁治, 陆滢, 等. 自体造血干细胞移植治疗复发难治性外周T细胞淋巴瘤疗效及预后分析[J]. 中华全科医学, 2020, 18(1): 59-61, 157. doi: 10.16766/j.cnki.issn.1674-4152.001168 Chen D, Pei R Z, Lu Y, et al. Efficacy and prognosis of autologous hematopoietic stem cell transplantation in treating recurrent refractory peripheral T cell lymphoma[J]. Chinese Journal of General Practice, 2020, 18(1): 59-61, 157. doi: 10.16766/j.cnki.issn.1674-4152.001168
[2]	中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国CASTLEMAN病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(7): 529-534. Hematology Committee of Chinese Medical Association, Hematological Oncology Committee of China Anti-Cancer Association, China Castleman Disease Network (CCDN). The consensus of the diagnosis and treatment of Castleman disease in China (2021)[J]. Chinese Journal of Hematology, 2021, 42(7): 529-534.
[3]	DISPENZIERI A, FAJGENBAUM D C. Overview of Castleman disease[J]. Blood, 2020, 135(16): 1353-1364. doi: 10.1182/blood.2019000931
[4]	CARBONE A, BOROK M, DAMANIA B, et al. Castleman disease[J]. Nat Rev Dis Primers, 2021, 7(1): 84. doi: 10.1038/s41572-021-00317-7
[5]	MURAKAMI M, JOHKOH T, HAYASHI S, et al. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan[J]. Mod Rheumatol, 2020, 30(5): 843-851. doi: 10.1080/14397595.2019.1704983
[6]	FAJGENBAUM D C, JUNE C H. Cytokine Storm[J]. N Engl J Med, 2020, 383(23): 2255-2273. doi: 10.1056/NEJMra2026131
[7]	PIERSON S K, SHENOY S, OROMENDIA A B, et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease[J]. Blood Adv, 2021, 5(17): 3445-3456. doi: 10.1182/bloodadvances.2020004016
[8]	GOODMAN A M, JEONG A R, PHILLIPS A, et al. Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease[J]. Eur J Haematol, 2021, 107(6): 642-649. doi: 10.1111/ejh.13702
[9]	PATEL J P, PATEL D P, AMIN T H, et al. Castleman disease: a rare lymphoproliferative disorder with diverse clinical presentation, diagnosis, and treatment approach[J]. Cureus, 2024, 16(9): e69149. DOI: 10.7759/cureus.69149.
[10]	GAO Y H, LIU Y T, ZHANG M Y, et al. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival[J]. Br J Haematol, 2024, 204(5): 1830-1837. doi: 10.1111/bjh.19334
[11]	ZHANG M Y, JIA M N, CHEN J, et al. UCD with MCD-like inflammatory state: surgical excision is highly effective[J]. Blood Adv, 2021, 5(1): 122-128. doi: 10.1182/bloodadvances.2020003607
[12]	LANG E, VAN RHEE F. Idiopathic multicentric Castleman disease: an update in diagnosis and treatment advances[J]. Blood Rev, 2024, 64: 101161. DOI: 10.1016/j.blre.2023.101161.
[13]	GUNDUZ E, KIRKIZLAR H O, UMIT E G, et al. Castleman disease: a multicenter case series from turkey[J]. Turk J Haematol, 2022, 39(2): 130-135.
[14]	黄秀娟, 张新莲, 魏小芳, 等. Castleman病患者的临床特征及预后分析[J]. 中国实验血液学杂志, 2023, 31(1): 135-140. Huang X J, Zhang X L, Wei X F, et al. Clinical features and prognosis of patients with Castleman's disease[J]. Journal of Experimental Hematology, 2023, 31(1): 135-140.
[15]	徐才刚, 王雪梅. 血管免疫母细胞性T细胞淋巴瘤的诊治进展与展望[J]. 西南医科大学学报, 2024, 47(6): 471-475, 487. Xu C G, Wang X M. Review of advances in diagnosis and treatment of angioimmunoblastic T cell lymphoma[J]. Journal of Southwest Medical University, 2024, 47(6): 471-475, 487.
[16]	侯小燕, 朱尊民. 血管免疫母细胞性T细胞淋巴瘤病理和基因特征及治疗的研究进展[J]. 中华实用诊断与治疗杂志, 2023, 37(3): 321-324. Hou X Y, Zhu Z M. Pathological and genetic characteristics and treatment of angioimmunoblastic T-cell lymphoma[J]. Journal of Chinese Practical Diagnosis and Therapy, 2023, 37(3): 321-324.
[17]	XU L, LI J, XU X, et al. Plasma cell type Castleman's disease of lacrimal gland: a case report and literature review[J]. BMC Ophthalmol, 2024, 24(1): 508. doi: 10.1186/s12886-024-03775-1